38 Years of Experience in a Single Centre on Neuroendocrine Pancreatico-Duodenal Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome Abstract #1093

Introduction: Multiple Endocrine Neoplasia type 1 (MEN1) syndrome has an autosomal dominant transmission. Combination of tumors: parathyroid, pituitary and pancreatico-duodenal (PD) NETs. PD NETs in MEN1 syndrome show propensity for malignant degeneration.
Aim(s): We evaluated occurrence of PD, therapeutic strategies and follow up (FU) of PD NETs in MEN1 patients observed in our Unit.
Materials and methods: From 1975 to 2013: 322 PD NETs, 40/322 had a MEN1 syndrome. Average 40.5 years (range 13-69 yrs), 20 M/20 F. Only patients with MEN1 syndrome and a PD NET diagnosed by imaging or histology were included. FU to December 2013
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Doctor Valbona Lico

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1509 MEN1 Syndrome with Pancreatic Involvement and Synchronous Lung Adenocarcinoma: A Case Report
Introduction: Lung lesions in MEN1 patients makes us consider firstly a neuroendocrine tumor (NET) as carcinoids are part of MEN1 syndrome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: Doctor Valbona Liço
Keywords: men1
#2925 A Single Centre Experience of Open Surgery for Pancreatic Insulinomas on 88 Patients
Introduction: Insulinomas are functioning pancreatic neuroendocrine neoplasms (NENs), typically small and with a benign clinical course in more than 90% of cases.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#2931 One-Stage Middle-Preserving Pancreatectomy: Indications and Outcomes
Introduction: Parenchyma-sparing surgical techniques are used in pancreatic surgery to preserve organ function. Middle-preserving pancreatectomy (MPP) may be an alternative to total pancreatectomy (TP) in benign/borderline disease that does not affect pancreatic body.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier